Expression and characterization of SARS-CoV-2 spike proteins.
Nat Protoc
; 16(11): 5339-5356, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1454802
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 spike protein is a critical component of coronavirus disease 2019 vaccines and diagnostics and is also a therapeutic target. However, the spike protein is difficult to produce recombinantly because it is a large trimeric class I fusion membrane protein that is metastable and heavily glycosylated. We recently developed a prefusion-stabilized spike variant, termed HexaPro for six stabilizing proline substitutions, that can be expressed with a yield of >30 mg/L in ExpiCHO cells. This protocol describes an optimized workflow for expressing and biophysically characterizing rationally engineered spike proteins in Freestyle 293 and ExpiCHO cell lines. Although we focus on HexaPro, this protocol has been used to purify over a hundred different spike variants in our laboratories. We also provide guidance on expression quality control, long-term storage, and uses in enzyme-linked immunosorbent assays. The entire protocol, from transfection to biophysical characterization, can be completed in 7 d by researchers with basic tissue cell culture and protein purification expertise.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Gene Expression Regulation, Viral
/
Spike Glycoprotein, Coronavirus
/
SARS-CoV-2
Topics:
Vaccines
/
Variants
Limits:
Animals
/
Humans
Language:
English
Journal:
Nat Protoc
Year:
2021
Document Type:
Article
Affiliation country:
S41596-021-00623-0
Similar
MEDLINE
...
LILACS
LIS